---
title: "Patent Expiry"
description: "Patent expiry enabled generic semaglutide launch in India, reducing GLP-1 therapy costs."
canonical: "https://www.kesho.health/glossary/patent-expiry"
markdown_url: "https://www.kesho.health/md/glossary/patent-expiry"
language: "en-IN"
---

# Patent Expiry

**Canonical HTML:** https://www.kesho.health/glossary/patent-expiry  
**Markdown:** https://www.kesho.health/md/glossary/patent-expiry

## Definition

Patent expiry occurs when intellectual property protection ends, allowing other manufacturers to produce generic versions of a medicine.

## Extended

Semaglutide patent developments allowed Indian companies to launch CDSCO-approved generics in 2024–2026, improving affordability for diabetes and obesity patients paying out of pocket. In India, these concepts appear in RSSDI and ICMR guidance for type 2 diabetes and obesity care—always confirm details with your prescribing physician.

## Learn more

[Full guide](https://www.kesho.health/blog/glp-1-cost-india-2026) · [MD](https://www.kesho.health/md/blog/glp-1-cost-india-2026)

## Related terms

- [generic-drug](https://www.kesho.health/glossary/generic-drug)
- [semaglutide](https://www.kesho.health/glossary/semaglutide)